Redx Pharma
Redx Pharma is a clinical-stage biotech developing novel small molecule therapeutics for fibrotic disease and cancer.
Its pipeline is anchored by zelasudil, a selective ROCK2 inhibitor in clinical development for idiopathic pulmonary fibrosis and other fibrotic indications, and zamaporvint, a Porcupine inhibitor targeting Wnt-ligand dependent tumours.
The company has a strong track record of out-licensing discovery assets, with programmes partnered with AstraZeneca, Jazz Pharmaceuticals and Loxo Oncology.
Latest News
Redx Pharma Unveils Design of ROCKETEER Phase 2 Trial of RXC008 in Fibrostenotic Crohn's Disease
Redx Pharma has unveiled the design of ROCKETEER, a Phase 2 trial of its GI-restricted pan-ROCK inhibitor RXC008 in fibrostenotic Crohn's disease, with first patient enrolment expected in 2026. The randomised, placebo-controlled trial will enrol around 180 patients across North America, Europe and the UK, with a primary endpoint of change in stricture length on magnetic resonance enterography at week 24, an endpoint shaped by FDA input.
Redx Pharma appoints Mei-Lun Wang as chief medical officer
Redx Pharma has appointed Dr Mei-Lun Wang, a paediatric gastroenterologist with over 25 years of clinical and drug development experience, as chief medical officer. The appointment follows the addition of gastroenterologist Dr Bernard Coulie to Redx's board on 27 August 2026, further bolstering the company's gastroenterology expertise around lead candidate RXC008 for fibrostenotic Crohn's disease.
Redx Pharma to Merge with Skye Bioscience, Backed by $125m Financing
Redx Pharma has entered a definitive transaction agreement to be acquired by Nasdaq-listed Skye Bioscience via a scheme of arrangement, with the combined company trading as Fibrx Therapeutics and led by Redx's current management team and board. The combination is backed by approximately $125 million in concurrent financings, including a $36 million Series A led by new investor Abingworth. The Series A completed on 27 August, bringing Andrew Sinclair (Abingworth) and Bernard Coulie onto the Redx board; the wider transaction remains expected to complete in Q4 2026.